BioAtla (BCAB) Scheduled to Post Earnings on Thursday

BioAtla (NASDAQ:BCAB - Get Free Report) will be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

BioAtla (NASDAQ:BCAB - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01. During the same quarter in the previous year, the firm posted ($0.75) EPS. On average, analysts expect BioAtla to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioAtla Stock Up 8.9 %

Shares of NASDAQ:BCAB traded up $0.17 during trading on Friday, reaching $2.09. 467,551 shares of the company's stock traded hands, compared to its average volume of 826,436. BioAtla has a fifty-two week low of $1.14 and a fifty-two week high of $4.02. The company has a 50-day simple moving average of $1.87 and a 200-day simple moving average of $1.90. The firm has a market cap of $101.03 million, a PE ratio of -0.94 and a beta of 1.06.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a "market outperform" rating and issued a $5.00 target price on shares of BioAtla in a report on Monday, September 16th.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.